Moreover, in describing a novel BCL3 inhibitor with anti-cancer properties in models of breast cancer [111], we have reported on the transcriptional responses of a panel of key NFkB-responsive genes to BCL3 inhibition mediated both by siRNA and pharmacologically. This evidence concerns the gene BCL3 and breast carcinoma.